Indegene growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	2 yr
Revenue	+23.7%	+16.4%
EBITDA	+15.9%	+10.7%
Net Income	−1.4%	+9.2%
EPS (adj.)	−1.4%	+7.9%
Total Assets	+39.0%	+34.7%
Total Equity	+20.0%	+48.2%
Free Cash Flow	+47.3%	+10.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDGN₹593.45

Indegene Ltd.

· Pharma & Health

₹ CrorePeersSYNGENE LTTS GRANULES JUBLPHARMA KIMS ERIS EMCURE ONESOURCEMcap ₹14,272 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	2Y CAGR
Revenue	+23.7	+16.4
EBITDA	+15.9	+10.7
Net Income	-1.4	+9.2
EPS (adj.)	-1.4	+7.9
Total Assets	+39.0	+34.7
Total Equity	+20.0	+48.2
Free Cash Flow	+47.3	+10.5

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.